Retrovirus vectors derived from avian sarcoma leukosis viruses permitting transfer of genes into mammalian cells and therapeutic uses thereof

US6794188B2 · kind B2 · utility

Assignee

• The United States of America, as represented by the Department of Health and Human Services · US

Inventors

• Eugene Barsov · Frederick, US
• Stephen H. Hughes · Smithsburg, US

Key dates

• Filing date: Sep 24, 2001
• Grant date: Sep 21, 2004
• Expiry date: Sep 24, 2021

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2840/44
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Recombinant avian sarcoma leukosis virus (ASLV)-derived retrovirus vectors having an expanded host range are described. The host range is expanded by the replacement of the ASLV envelope gene by an envelope gene from a virus capable of infecting both mammalian and avian cells. The resulting recombinant ASLV-derived retroviral vectors can replicate efficiently in avian cells, infect both avian and mammalian cells in high titer, and are replication-defective in mammalian cells. Thus, they are quite safe and advantageous for use in gene therapy and vaccines.